Want to see AU:MSB full AI Analyst Report?
MSB Stock Chart & Stats
AU$2.35
-AU$0.08(-3.60%)
At close: 4:00 PM EDT
AU$2.35
-AU$0.08(-3.60%)
Day’s Range― - ―
52-Week RangeAU$1.88 - AU$3.31
Previous CloseN/A
Volume2.85M
Average Volume (3M)2.59M
Market Cap
AU$3.04B
Enterprise ValueAU$3.52K
Total Cash (Recent Filing)AU$129.57M
Total Debt (Recent Filing)AU$135.14M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 04, 2027EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,298,748,200
10 Day Avg. Volume2,996,007
30 Day Avg. Volume2,593,600
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)3.09
Price to Sales (P/S)14.29
P/FCF Ratio-39.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.64Price Target Upside54.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$200.02M
Bulls Say, Bears Say
Bulls Say
Ryoncil Commercial TractionRyoncil has established an initial commercial revenue base and management expects further growth. This gives Mesoblast a clearer path from clinical development toward recurring product revenue, improving operating leverage as adoption expands.
Broad Market Access And High Gross MarginBroad payer access and favorable policies reduce reimbursement friction and support durable uptake. The very high gross margin also creates substantial contribution potential, allowing future revenue growth to fund commercialization and development.
Late-Stage Pipeline ProgressCompletion of treatment in a pivotal trial advances a potentially valuable second product opportunity beyond Ryoncil. A successful outcome could diversify revenue, expand the addressable market, and strengthen Mesoblast's long-term platform value.
Bears Say
Persistent Losses And Cash BurnMesoblast remains dependent on external funding while operating cash flow is negative and profitability has not been demonstrated. Continued losses can constrain investment capacity and increase financing or dilution risk before products generate sustainable cash.
Ryoncil Revenue ConcentrationDependence on one product leaves near-term revenue exposed to adoption, reimbursement, manufacturing, and regulatory execution. Pipeline candidates may eventually diversify the business, but they remain developmental and cannot yet offset concentration risk.
High Development And Commercialization CostsLarge clinical, regulatory, manufacturing, and sales investments are required to support the pipeline and launch. These costs may delay profitability and create execution risk if additional approvals or commercial growth take longer than expected.
Mesoblast Limited News
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$1.88 and its highest was AU$3.31 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$3.04B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Mar 04, 2027 which is in 182 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.043 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.033.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is -0.02.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,298,748,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.043 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.64 (54.75% Upside)
AU$3.64 (54.75% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 96%
Sector Average 60%
Sector Average 60%
News Sentiment
Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
MSB Stock 12 Month Forecast
Average Price Target
AU$3.64
▲(54.75% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―